Use of a recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) 2:1 combination for controlled ovarian stimulation during assisted reproductive technology treatment: A real-world study of routine practice in the Russian Federation-Reference-Cited by-同舟云学术

Use of a recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) 2:1 combination for controlled ovarian stimulation during assisted reproductive technology treatment: A real-world study of routine practice in the Russian Federation

Published:2022-12 Issue: Volume:85 Page:134-148
ISSN:1521-6934
Container-title:Best Practice & Research Clinical Obstetrics & Gynaecology
language:en
Short-container-title:Best Practice & Research Clinical Obstetrics & Gynaecology

Author:

Koloda Yulia^ORCID,Korsak Vladislav,Rozenson Oleg,Anshina Margarita,Sagamonova Karina,Baranov Igor,Yakovenko Sergey,D'Hooghe Thomas,Ershova Anna,Lispi Monica

Funder

Merck KGaA

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,General Medicine

Reference38 articles.

1. Reduced FSH and LH action: implications for medically assisted reproduction;Bosch;Hum Reprod,2021

2. International committee for monitoring assisted reproductive technology (ICMART) and the world Health organization (WHO) revised glossary of ART terminology, 2009;Zegers-Hochschild;Fertil Steril,2009

3. Russian summary of product characteristics;Pergoveris,2017

4. The poor responder in IVF: is the prognosis always poor?: a systematic review;Oudendijk;Hum Reprod Update,2012

5. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders;Humaidan;Hum Reprod,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preface: Emerging importance of real world evidence in reproductive medicine;Best Practice & Research Clinical Obstetrics & Gynaecology;2024-02

2. WITHDRAWN:Â Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35–40 years: A German database study;Best Practice & Research Clinical Obstetrics & Gynaecology;2023-07